

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 726 072 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

14.08.1996 Bulletin 1996/33

(51) Int. Cl.⁶: **A61K 31/415**, A61K 45/06

(21) Application number: **96101756.3**

(22) Date of filing: **07.02.1996**

(84) Designated Contracting States:
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE**

(30) Priority: **08.02.1995 US 386366**

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY
Princeton, NJ 08543-4000 (US)**

(72) Inventors:

- **Powell, James R.**
Washington Crossing, PA 18977 (US)
- **Seymour, Andrea Ann**
Lambertville, NJ 08530 (US)
- **Trippodo, Nick C.**
Newtown, PA 18940 (US)

(74) Representative: **Josif, Albert, Dr.-Ing. et al**
Baaderstrasse 3
80469 München (DE)

(54) **Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor**

(57) Hypertension and/or congestive heart failure are treated with the combination of the angiotensin II antagonist 2-butyl-6,7,8,9-tetrahydro-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]nonan-4-one and a selective neutral endopeptidase inhibitor or a dual acting neutral endopeptidase inhibitor.

0 726 072 A2

Description

Darrow et al. in European Patent Application 498,361 disclose treating hypertension or congestive heart failure with a combination of an angiotensin II antagonist or a renin inhibitor with a neutral endopeptidase inhibitor.

5 Matsumoto et al., JASN, September 1993, disclose that the combined therapy of an angiotensin II blocker, DUP753, and a neutral endopeptidase inhibitor, candoxatril, may be useful in the treatment of congestive heart failure and renal failure.

Bernhart et al. in United States Patent 5,270,317 disclose a series of N-substituted heterocyclic derivatives which possess angiotensin II antagonist activity. Bernhart et al. disclose that such compounds can be used in the treatment
10 of various cardiovascular complaints, especially hypertension, heart failure, and venous insufficiency, as well as in the treatment of glaucoma, diabetic retinopathy and various complaints of the central nervous system. It is also disclosed that such compound can be used in combination with other active agents such as tranquilizers, beta-blocking compounds, a calcium antagonist, or a diuretic.


Selective neural endopeptidase inhibitors are taught by Delaney et al. in United States Patents 4,722,810 and
15 5,223,516 and the use of selective neutral endopeptidase inhibitors alone or in combination with angiotensin converting enzyme inhibitors to treat hypertension are disclosed by Delaney et al. U.K. Patent Application 2,207,351 and by Haslanger et al. in United States Patent 4,749,688. The treatment of congestive heart failure by administration of a combination of a selective neutral endopeptidase inhibitor and an angiotensin converting enzyme inhibitor is disclosed by Seymour in United States Patent 5,225,401.

20 Compounds possessing both neutral endopeptidase and angiotensin converting enzyme inhibition activity are disclosed by Flynn et al. in United States Patent 5,366,973, European Patent Application 481,522 and PCT Patent Applications WO 93/16103, and WO 94/10193, Warshawsky et al. European Patent Applications 534,363, 534,396 and 534,492, Fournie-Zaluski European Patent Application 524,553, Karanewsky et al. European Patent Application 599,444, Karanewsky European Patent Application 595,610, Robl et al., European Patent Application 629,627, Robl
25 United States Patent 5,362,727 and European Patent Application 657,453.

This invention is directed to the discovery that the angiotensin II antagonist 2-butyl-6,7,8,9-tetrahydro-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]nonan-4-one acts synergistically with a selective neutral endopeptidase inhibitor or a dual acting neutral endopeptidase inhibitor as defined below to reduce cardiac preload and afterload and enhance natriureses. The combination of this angiotensin II antagonist and the selective or dual acting
30 neutral endopeptidase inhibitor produced significant reductions in left ventricular end diastolic pressure (LVEDP) and left ventricular systolic pressure (LVSP) that were greater than those produced by either treatment alone. Thus, the combination of this particular angiotensin II antagonist and the selective or dual acting neutral endopeptidase inhibitor is useful in treating hypertension and/or congestive heart failure.

The angiotensin II antagonist employed within this invention is the compound 2-butyl-6,7,8,9-tetrahydro-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]nonan-4-one having the structural formula


(I)



known in the literature as SR47436, BMS 186295, or irbesartan and pharmaceutically acceptable salts thereof such as the potassium and sodium salts. These angiotensin II antagonists and their method of preparation are disclosed by Bernhart et al. in United States Patent 5,270,317.

The selective neutral endopeptidase inhibitor for use within this invention are those of the formula

(II)



and pharmaceutically acceptable salts thereof wherein:

R₂ is alkyl of 1 to 7 carbons, trifluoromethyl, phenyl, substituted phenyl, -(CH₂)_{1 to 4}-phenyl, or -(CH₂)_{1 to 4}-substituted phenyl;

R₃ is hydrogen, alkyl of 1 to 7 carbons, phenyl, substituted phenyl, -(CH₂)_{1 to 4}-phenyl, or -(CH₂)_{1 to 4}-substituted phenyl;

R₁ is hydroxy, alkoxy of 1 to 7 carbons, or NH₂;

n is an integer from 1 to 15; and

the term substituted phenyl refers to a substituent selected from lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, hydroxy, Cl, Br, or F.

Preferred are the selective neutral endopeptidase inhibitors of formula II wherein:

R₂ is benzyl;

R₃ is hydrogen;

n is an integer from 1 to 9; and

R₁ is hydroxy.

Most preferred for use in this invention is the selective neutral endopeptidase inhibitor of formula II reported in the literature as SQ 28,603 which is the compound of formula II wherein:

R₂ is benzyl;

R₃ is hydrogen;


n is one; and

R₁ is hydroxy.

The preparation of the selective neutral endopeptidase inhibitors of formula II wherein R₂ is other than trifluoromethyl are disclosed by Delaney et al. in United States Patent 4,722,810. The preparation of the selective neutral endopeptidase inhibitors of formula II wherein R₂ is trifluoromethyl are disclosed by Delaney et al in United States Patent 5,223,516.

Dual acting neutral endopeptidase inhibitors suitable for use within this invention are compounds which possess both neutral endopeptidase inhibiting activity and angiotensin converting enzyme inhibiting activity. Particularly useful are the dual acting inhibitors of the formula

(III)



and pharmaceutically acceptable salts thereof wherein:

p is one or two;

X is O or S;

m is zero or one;

Y is CH₂, S or O provided that Y is S or O only when m is one;

R₄ is hydrogen, alkyl of 1 to 7 carbons, phenyl, substituted phenyl, -(CH₂)_{1 to 4}-phenyl, -(CH₂)_{1 to 4}-substituted phenyl, cycloalkyl of 3 to 7 carbons, -(CH₂)_{1 to 4}-cycloalkyl of 3 to 7 carbons, heteroaryl, and -(CH₂)_{1 to 4}-heteroaryl;

R₅ is hydrogen, alkyl of 1 to 7 carbons, -(CH₂)_{1 to 4}-phenyl and -(CH₂)_{1 to 4}-substituted phenyl;

the term substituted phenyl refers to a substituent selected from lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, hydroxy, Cl, Br, or F; and

the term heteroaryl refers to monocyclic rings of 5 or 6 atoms containing one or two O and S atoms and/or one to four N atoms provided that the total number of heteroatoms in the ring is 4 or less and bicyclic rings wherein the 5 or 6 membered heteroaryl ring as defined above is fused to a benzene or pyridyl ring.

Preferred are the dual acting neutral endopeptidase inhibitors of formula III wherein:

R₄ is benzyl, cyclopropylmethyl, or straight or branched chain alkyl of 3 to 5 carbons;

p is one or two;

X is O or S;

m is zero or one;

Y is CH₂, S, or O provided that Y is S or O when m is one; and

R₅ is hydrogen.

Most preferred for use in this invention is the dual acting neutral endopeptidase inhibitor of formula III wherein:

R₄ is benzyl;

p is two;

Y is S;

m is one;


Y is CH₂; and

R₅ is hydrogen.

The dual acting neutral endopeptidase inhibitors of formula III are disclosed in European Patent Application 629,627 of Robl et al.


Also useful as neutral endopeptidase inhibitors for use within this invention are the dual acting inhibitors of the formula

(IV)




and pharmaceutically acceptable salts thereof wherein:

5




10

15



20

25




30

, or

35

40



45

R_4 , R_5 , and p are as defined above;

50

R_7 and R_8 are both hydrogen, or both alkyl of 1 to 7 carbons, or R_7 is hydrogen and R_8 is alkyl of 1 to 7 carbons, phenyl, $-(CH_2)_{1 \text{ to } 4}$ -phenyl and $-(CH_2)_{1 \text{ to } 4}$ -substituted phenyl, or R_7 and R_8 taken together with the carbon to which they are attached complete a cycloalkyl of 3 to 5 carbons.

R_9 is hydrogen or alkyl of 1 to 7 carbons.

Z is oxo or two hydrogens.

55

Preferred are the dual acting neutral endopeptidase inhibitors of formula IV wherein:

R_4 is benzyl;

R_7 and R_8 are both methyl;

R_9 is hydrogen or methyl, especially hydrogen;

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.